Ignite Creation Date:
2025-12-25 @ 5:00 AM
Ignite Modification Date:
2026-02-28 @ 5:29 AM
Study NCT ID:
NCT03932318
Status:
WITHDRAWN
Last Update Posted:
2023-07-20
First Post:
2019-04-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
Sponsor:
Actinium Pharmaceuticals
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
LIN-AC225-AML03
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None